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Tacrine is a reversible inhibitor of cholinesterase activity prescribed for symptomatic 
treatment of Alzheimer’s disease. Therapy with tacrine requires dose escalation and 
liver test monitoring[1] since it can induce a reversible liver toxicity, limiting their 
therapeutic use. Tacrine hepatotoxicity was also demonstrated in rat liver, reinforcing 
the belief that it is a direct toxicity rather than immunoallergy [2]. Despite the liver 
toxicity associated with treatment with tacrine, new compounds have been synthesized 
based on the tacrine, with the objective of obtaining more selective molecules and 
therefore less cytotoxic. 
The present work was aimed at studying the effect of two new tacrine analogues, 
acethylcholinesterase inhibitors synthesized from 4-amino-1H-pyrrole-3-carbonitrile, in 
comparison with tacrine, to evaluate the in vivo effect on liver and mitochondrial 
functionality of Wistar rats. We have previously showed the molecular mechanism 
underlying the impact on brain activity of tacrine and of these two novel tacrine 
analogues [3]. The evaluation of liver and kidney biomarkers shows that, contrarily to 
tacrine, the novel compounds (T1 and T2) were not toxic. Mitochondrial bioenergetics 
was significantly affected by tacrine, but T1 and T2 compounds did not induce any 
negative effect when used at the same concentration as tacrine. Using the comet assay 
we found that tacrine induce significant DNA damage in rat hepatocytes. Comet assay 
with cells digested in the presence of FPG enzyme shows that the DNA strand breaks 
were due oxidative processes. Tacrine significantly decrease calcium load capacity of 
mitochondria but T1 and T2 compounds does not show any significant effect on 
mitochondrial calcium load capacity. Our results clearly demonstrate that the two novel 
tacrine analogues were much less hepatotoxic and nephrotoxic than tacrine. The 
negative effect promoted by tacrine in mitochondrial bioenergetics was not observed 
with these two new compounds. From our results we can conclude that the novel 
compounds show no toxicological problems like tacrine, and therefore their 
pharmacological use could have benefits over tacrine. 
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